Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Roche will aim to tackle gene therapy challenges through Dyno Therapeutics collaboration, says GlobalData

Dyno Therapeutics has recently announced the formation of a new strategic partnership with Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. The partnership will see the utilization of artificial intelligence (AI), which is a key industry trend in the development of gene therapies in neurological disorders and could improve the […]
Read more

Egypt marks major achievement with malaria-free certification, but need for global R&D remains significant, says GlobalData

The World Health Organization (WHO) has certified Egypt as being malaria-free, following a near 100-year endeavour by the Egyptian government. Egypt is the third country to be declared malaria-free in the WHO Eastern Mediterranean Region, and the 44th country globally. However, hundreds of millions of cases of malaria are still reported worldwide each year. These […]
Read more

World Osteoporosis Day highlights need for comprehensive care strategies, says GlobalData

Marking World Osteoporosis Day on 20 October, the International Osteoporosis Foundation (IOF) brought worldwide attention to a crucial issue: the urgent need for robust osteoporosis screening and sustained care strategies to prevent fragility fractures. Under the theme “Say No to Fragile Bones,” it highlighted the gaps in diagnosis and treatment, stressing the importance of proactive […]
Read more

Asthma crisis in US marginalized communities from redlining requires more than just healthcare interventions, says GlobalData

Decades after the discriminatory practice of redlining was banned in the US, its lasting impact is still driving significant health disparities, particularly in asthma prevalence, according to recent studies. These findings highlight how the combination of poor housing conditions and environmental pollutants in historically redlined neighborhoods continues to fuel the asthma crisis, particularly among children. […]
Read more

Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection, says GlobalData

Australia’s Therapeutic Goods Administration (TGA) has recently decided not to register lecanemab (Leqembi) for patients with mild cognitive impairment (MCI) or mild dementia of Alzheimer’s disease (AD). Despite lecanemab demonstrating slowing of disease progression in pivotal trials, concerns about its safety profile have led to TGA’s decision. Against this backdrop, Eli Lilly’s donanemab that has been […]
Read more

NICE rejects second Alzheimer’s drug but opportunity remains for decision change, says GlobalData

Following the news that the National Institute for Health and Care Excellence (NICE) is not recommending Eli Lilly’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) Kisunla (donanemab) on the NHS following its approval by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease […]
Read more

Johnson & Johnson’s subcutaneous Tremfya holds potential to set new standard in Crohn’s disease treatment, says GlobalData

Johnson & Johnson‘s subcutaneous (SC) Tremfya (guselkumab) demonstrated strong results in the Phase III GRAVITI trial, marking a major breakthrough in the treatment of Crohn’s disease (CD). This patient-friendly regimen could enhance patient autonomy, improve adherence, and lead to better outcomes. The GRAVITI results position guselkumab as a significant new option in CD, says GlobalData, […]
Read more

UNI-494 trial results highlight Unicycive’s potential to differentiate in AKI space, says GlobalData

Unicycive Therapeutics recently announced positive results from its Phase I trial of UNI-494, showing that the drug’s use was observed to be safe and well-tolerated in both single ascending and multiple ascending doses. The trial results also showed that UNI-494 absorption was fast, rapidly metabolized, and plasma concentration increases when dose increases. The drug potentially […]
Read more

S1P receptor modulators face uncertain future in Crohn’s disease amid efficacy and trial setbacks, says GlobalData

Pfizer’s upcoming presentation at United European Gastroenterology Week (UEGW) 2024 will reveal the initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD), showing modest efficacy in endoscopic response and remission rates. With its in-class competitor ozanimod also underperforming in trials, the outlook for S1P receptor modulators […]
Read more

Global leaders unite to combat AMR: targets set at UNGA are urgently needed, says GlobalData

In a crucial step forward, world leaders at the United Nations General Assembly (UNGA) have pledged to reduce antimicrobial resistance (AMR) associated fatalities by 10% by 2030. This declaration, which emphasizes a multi-sector approach, reflects a necessary shift toward a comprehensive “One Health” approach, integrating human, animal, and environmental health. By prioritizing collaboration and innovative […]
Read more

A schizophrenia win for BMS’s Cobenfy, but challenges lie ahead, says GlobalData

Bristol Myers Squibb (BMS) has recently secured approval from the US FDA for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia. Cobenfy has a mechanism of action (MOA) distinct from traditional antipsychotics. However, as the drugs most widely used to treat schizophrenia are inexpensive, genericized atypical antipsychotics, the schizophrenia market is […]
Read more
1 … 13 14 15 16 17 … 108